Clik here to view.
Immunochemical Engineering of Cell Surfaces: A Conversation with Dr. Jia Xie
Countdown Researcher Jia Xie discusses a cutting-edge treatment in development by Dann Dulin Jia Xie, PhD. Photo by Madeline McCurry-Schmidt Block HIV by using the body’s own immune cells? Is it truly...
View ArticleTANGO Study Starts
In February 2018, ViiV Healthcare announced the start of a forty-eight-week phase III study designed to determine whether adults with HIV-1 who have achieved a suppressed viral load on a tenofovir...
View ArticleClik here to view.
Janssen Announces FDA Approval of SYMTUZA
The Janssen Pharmaceutical Companies of Johnson & Johnson announced on July 18, 2018 that the U.S. FDA has approved the use of SYMTUZA, the only complete darunavir-based singled-tablet regimen...
View ArticleClik here to view.
Use of HIV Preexposure Prophylaxis May Increase Use of Primary Care
A new study reveals that patients who use PrEP (Pre-exposure Prophylaxis ), a combination of the antiretroviral medications emtricitabine and tenofovir called Truvada, to prevent HIV infection, tend to...
View ArticleClik here to view.
Dual Regimens in Trials Show Promise
The Power of Two Dual regimens show promise in clinical trials by Chael Needle At the International AIDS Conference in Amsterdam last July, ViiV Healthcare shared its latest research with attendees....
View ArticleClik here to view.
Under One Roof: ViiV Healthcare Strives for New HIV Treatments
If we think of HIV as carrying a kind of a malware that takes over human T cells and turns them into a machine to create more copies of itself, then the goal has always been to try and cripple some...
View ArticleFDA Approves New HIV Treatments
The U.S. Food and Drug Administration (FDA) has approved pharmaceutical giant Merck’s Delstrigo and Pifeltro for the treatment of HIV-1 infection in adult patients with no prior antiretroviral...
View ArticleClik here to view.
An HIV Injectable Regimen Comes of Age
Without the Pill Box? The First Long-Acting Injectable Regimen for Individuals Living with HIV Comes of Age by Mel Baker A funny thing happened on the way to the 2019 Conference on Retroviruses and...
View ArticleViiV’s Dolutegravir Dual Therapy Works for Both First-Line & Maintenance...
ViiV’s Dolutegravir Dual Therapy Works for Both First-Line & Maintenance Treatment Findings from the GEMINI and TANGO studies, reported at the 10th International AIDS Society Conference on HIV...
View ArticleClik here to view.
TAG’s Pipeline Report
Pipeline Report Treatment Action Group provides updates on treatments for HIV, HCV & TB by Hank Trout Treatment Action Group (TAG) has announced the release of the first sections of their 2019...
View ArticleClik here to view.
Highest HIV Viral Suppression Rate in New Ryan White Program
Highest HIV Viral Suppression Rate in New Ryan White Program In its fifth annual publication of national client-level data from the Ryan White HIV/AIDS Program Services Report (RSR), the Health...
View ArticleClik here to view.
Optimal ARTs for Older Adults with HIV
Optimal ARTs for Older Adults with HIV Cheerful senior gentleman posing with an AIDS badge on his shirt isolated on white background. Photo by iStock Recently, the HIV-Age.org website published the...
View ArticleClik here to view.
Global HIV and COVID-19 Emergency Response Fund
Global HIV and COVID-19 Emergency Response Fund On April 27, 2020, ViiV Healthcare announced the creation of £3-million Global HIV and COVID-19 Emergency Response Fund to provide financial resources to...
View ArticleClik here to view.
Injection Breakthrough
Injection Breakthrough FDA Approves a Complete Long-Actimng Injectable Regimen for HIV Treatment by Hank Trout On January 21, 2021, The U.S. Food and Drug Administration (FDA) approved Cabenuva, a...
View Article
